Drug Database
PO

polio vaccine (OPV, Bio Farma / tOPV, Bio Farma)

✓ Approved

Bio Farma · Vaccine · Vaccine

What is polio vaccine?

polio vaccine is a vaccine developed by Bio Farma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesOPV, Bio Farma, tOPV, Bio Farma
CompanyBio Farma
Drug ClassVaccine, Large Molecules
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Bio Farma

Therapeutic Indications

polio vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresPolio immunisation✓ Approved

Related Research Articles

PubMedNature communications2026-10-16

Klebsiella-dominant gut communities are associated with impeded oral rotavirus vaccine response in infants.

Seymour Cale O CO, Ecklu-Mensah Gertrude G, Lee Yesun Y, Nicols Alexander R AR et al.

Rotavirus gastroenteritis is the leading cause of infant diarrheal death worldwide. Oral rotavirus vaccine (RVV) prevents illness and death, but efficacy differs between high- and low-income countries and the etiologies are unclear. Here, we describe the relationship between colonization of the infant gut by commensal bacteria, inflammation, and vaccine response across a cohort of infants from Panama, Peru, and the U.S. Vaccine immunogenicity was related to community composition in the first month of life and inverse to increased relative abundance of Klebsiella. Clustering communities into gut types revealed that microbiome configurations with elevated Klebsiella or Escherichia in the first month of life were negatively associated with both seroconversion and rotavirus shedding after vaccination, suggesting potential inhibition of vaccine function or host response. Infants without RVV strain shedding displayed elevated fecal calprotectin in the first month. These results implicate microbiome-augmented infant gut inflammation as a potential impediment to RVV response.

PMID 42881193
Read full article →
PubMedNature communications2026-10-16

Effectiveness of the oral rotavirus vaccine ROTASIIL among children hospitalized with acute gastroenteritis in India.

Chaudhary Varsha Sudhir VS, Machathi Anupama A, Kharat Namrata N, Lingam Ragavi R et al.

ROTASIIL®, a pentavalent oral rotavirus vaccine licensed in India in 2017, was introduced into the Universal Immunization Program in 2018. Primary endpoint was vaccine effectiveness (VE) against moderate and severe rotavirus gastroenteritis (RVGE) in children <2 years using pooled data from two multi-center observational studies across 32 hospitals in seven states (July 2019-December 2023). A test-negative case-control design estimated adjusted VE (aVE) for three ROTASIIL® doses. Among 2,243 children aged 3-23 months hospitalized with acute gastroenteritis, 638 were ELISA-positive. For completed series (three doses), the aVE against hospitalization due to RVGE among children aged 3-23 months was 52% (95% CI, 32-66), with the highest aVE of 88% (CI, 53-97) observed among those aged 3-5 months. The aVE against moderate RVGE was 56% (CI, 11-79), and that of severe RVGE was 54% (CI, 31-70). The highest genotype-specific aVE was 62% (CI, 29-80) against G1P[8]. For at least one dose, the aVE was 45% (CI, 26-60) among children aged 1-23 months. A completed series of ROTASIIL® effectively reduced RVGE hospitalizations especially with a higher VE observed in younger age groups, suggesting the benefits of timely immunization.

PMID 42881148
Read full article →
PubMedJournal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes2026-10-16

Effects of a bioherbicide and a chemical herbicide on soil microbial community structure, diversity, and nitrogen cycling functions.

Deng Quan Q, Lv Liangchen L, Feng Huaqi H, Liu Dongyang D et al.

The fermentation broth of the bioherbicidal fungus Aspergillus versicolor D5 shows efficacy against dicotyledonous weeds in tobacco fields. However, little is known about its impact on the soil ecological environment of tobacco fields, particularly in comparison with chemical herbicides. This study compares the effects of a bioherbicide (BIO) and rimsulfuron (CHE) on tobacco field soil ecology. Both show comparable weed control efficacy and increase urease and dehydrogenase activities, although BIO causes a smaller urease increase. Unlike CHE, BIO does not inhibit nitrite reductase. Metagenomics shows that BIO slightly alters community structure without reducing diversity, whereas CHE decreases it. BIO increases the abundance of Luteitalea (involved in decomposing complex organic carbon and nitrogen cycling) and Chloracidobacterium (light-assisted carbon metabolism) within the phylum Acidobacteria, whereas CHE significantly reduces the abundance of these bacteria. BIO decreases the abundance of arbuscular mycorrhizal fungi Rhizophagus and Funneliformis, while CHE increases them. Nitrogen cycling analysis shows that BIO only significantly reduces the anammox pathway, causing little overall disturbance, whereas CHE strongly promotes dissimilatory/assimilatory nitrate reduction and nitrate/nitrite uptake pathways. These findings indicate that the fermentation extract of A. versicolor D5 affects soil ecology less than rimsulfuron, causing less disturbance to soil microbial diversity in this study.

PMID 42885446
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Immune Profiles Elicited by Different HBV Vaccine Modalities and Their Associations with Serological and Intrahepatic Viral Outcomes.

Xiao Huiying H, He Jinhang J, Zhu Lili L, Wang Songmei S et al.

Therapeutic vaccination for chronic hepatitis B aims to restore HBV-specific T-cell immunity and contribute to a functional cure. We systematically compared the immune profiles and antiviral efficacy of four vaccine modalities: recombinant HBsAg (rHBsAg), antigen-antibody immune complex (IC), a DNA vaccine encoding HBsAg (DNA-HBsAg), and an HBsAg-Fc fusion DNA vaccine (DNA-HBsAg-Fc). In naïve mice, the rHBsAg vaccine predominantly induced anti-HBs IgG responses, whereas the IC vaccine elicited strong anti-HBs IgG and detectable CD4+ T-cell responses. In contrast, DNA vaccines preferentially induced HBsAg-specific CD8+ T-cell immunity, which was further enhanced by fusion to the Fc fragment of human IgG1. In the pre-immunization/AAV-HBV model, high anti-HBs titers in rHBsAg and IC groups were associated with rapid clearance of circulating HBsAg but not with comparable reductions in HBcAg+ hepatocytes, whereas stronger HBsAg-specific CD8+ T-cell responses in the DNA vaccine groups were associated with greater reductions in HBcAg+ hepatocytes. However, in the therapeutic AAV-HBV model, all vaccine monotherapies showed limited and non-sustained antiviral efficacy, with only transient reductions in serum HBsAg and limited reductions in HBcAg+ hepatocytes. These findings highlight the distinct immune profiles of different vaccine platforms and an association between stronger HBsAg-specific CD8+ T-cell responses and reduced intrahepatic HBcAg expression, while underscoring the limited efficacy of vaccine monotherapy in the AAV-HBV model.

PMID 42883747
Read full article →
PubMedMilitary medicine2026-10-16

The Case for Dedicated Vaccine Communication Training: A Survey of Military Pediatricians.

Auvil Daley D, Jones Katherine K, Ratusnik Rebecca R, Adams Daniel J DJ

Vaccine uncertainty is rising among families in the United States, even among military families. The ACGME mandates that pediatric residents be trained in effective communication strategies for patients and families hesitant about recommended vaccinations, yet few validated curriculum tools exist. We aimed to understand the current landscape of vaccine uncertainty experienced by military general pediatricians and see what communication strategies were routinely being implemented in clinical practice. In March 2025, 45 graduates of a mid-sized military pediatrics residency program from the years 2016-2024 who were currently practicing general pediatricians were invited to participate in a survey on vaccine communication in clinical practice. The survey was a mix of quantitative questions asking for experienced trends in vaccine uncertainty as well as open-ended questions about communication strategies being implemented. Three clinical researchers performed a manual thematic analysis of free-text answers to understand and quantify common themes. Thirty-seven general pediatricians (82%) responded, and 95% of those surveyed rated a curriculum during medical training on vaccine communication as "very" or "extremely important." Only 19% of physicians were able to recall formal training in addressing vaccine hesitancy during medical school, and only 62% during residency. The 3 most commonly declined vaccines were COVID-19, influenza, and HPV. Pediatricians reported using communication strategies focused on knowledge-sharing (65%), partnership with families (62%), and normalizing vaccines (40%). Common barriers to vaccine acceptance were mistrust and disinterest, most commonly with unwillingness to engage in a conversation. Most practicing military pediatricians who graduated from our residency program report a rise in vaccine uncertainty in their practice and agree that a residency curriculum on vaccine communication is highly important. Such curricula should encourage evidence-based communication styles using vaccine normalization while de-emphasizing the urge to combat misinformation using knowledge-sharing and should specifically address the most commonly declined immunizations.

PMID 42885154
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Production, Optimization and Characterization of Biobased Itaconic Acid from Saccharomyces cerevisiae.

Velioglu Tosuner Zulfiye Z, Kosaca Mehdi M, Ozturk Urek Raziye R, Yilmaz Onur O et al.

Itaconic acid (IA) is an important bio-based platform chemical with applications in the production of polymers, coatings, resins, and other value-added materials. However, its conventional microbial production relies predominantly on microorganisms that present safety and process-related limitations. This study investigated Saccharomyces cerevisiae BY4742 as a potentially safer microbial platform for the production of bio-based IA under submerged fermentation conditions. IA production was optimized using response surface methodology with a Box-Behnken design, considering glucose concentration, initial pH, and CaCI2 concentration as independent variables. The maximum IA concentration of 1133.50 ± 54.92 mg/L was obtained at 30 °C, pH 4.5, with 10% (w/v) glucose and without CaCI2 supplementation after 216 h of fermentation. The fermentation-derived IA was subsequently recovered and characterized using high-performance liquid chromatography, Fourier-transform infrared spectroscopy, 1H-nuclear magnetic resonance (1H-NMR), and thermogravimetric analysis. The analytical results confirmed the molecular identity and high chromatographic purity of the recovered IA. Furthermore, the homopolymerization ability of the fermentation-derived IA was evaluated and compared with that of commercial IA under the same reaction conditions. The 1H-NMR results demonstrated changes consistent with consumption of the IA C=C double bond following polymerization, indicating that the fermentation-derived IA retained its ability to undergo homopolymerization. Overall, these findings demonstrate the potential of S. cerevisiae for producing structurally confirmed bio-based IA and provide a proof of concept for its use as a renewable monomer for poly(itaconic acid) synthesis, supporting its further investigation for the development of bio-based polymeric materials.

PMID 42884165
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about polio vaccine